- Novartis AG NVS said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.
- The company is developing and marketing the product under a license agreement with Genmab A/S GMAB.
- The approval follows a positive opinion issued for subcutaneous ofatumumab by the CHMP of the European Medicines Agency in January this year.
- Ofatumumab is a fully human CD20 monoclonal antibody. It is self-administered by a once-monthly injection, delivered subcutaneously.
- Price Action: NVS shares closed 0.7% lower at $87.35 on Monday; GMAB shares are up 0.3% higher at $32.2 in premarket trading on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
